Imipenem Cilastatin Injection
Last Updated: November 11, 2016
Status: Current
Products Affected - Description
Primaxin injection, Merck
250 mg/ 250 mg, vial, 25 count (NDC 00006-3514-58) - discontinued
Reason for the Shortage
- Fresenius Kabi had imipenem and cilastatin sodium injection on shortage due to increased demand.
- Hospira had imipenem and cilastatin sodium injection on shortage due to manufacturing delays.
- Merck has discontinued Primaxin ADD-Vantage vials as well as the 250 mg vials. Merck has Primaxin 500 mg vials available.
Available Products
Primaxin injection, Merck
500 mg/500 mg, vial, 25 count (NDC 00006-3516-59)
Imipenem and Cilastatin Sodium injection, Fresenius Kabi
250 mg/250 mg, vial, 10 count (NDC 63323-0349-20)
250 mg/250 mg, vial, 10 count (NDC 63323-0349-20)
250 mg/250 mg, vial, 25 count (NDC 63323-0349-25)
500 mg/500 mg, vial, 10 count (NDC 63323-0322-20)
500 mg/500 mg, vial, 25 count (NDC 63323-0322-25)
Imipenem and Cilastatin Sodium injection, Hospira
500 mg/500 mg, vial, 25 count (NDC 00409-3507-01)
500 mg/500 mg, vial, 25 count (NDC 00409-3507-01)
250 mg/ 250 mg, vial, 25 count (NDC 00409-3508-01)
Estimated Resupply Dates
All marketed presentations are available.
Updated
November 11, August 1, July 27, June 24 and 10, May 4, April 12, February 25 and 3, January 13, 2016; December 17, November 20 and 11, October 27 and 12, September 16, August 21 and 4, July 10, June 11 and 8, May 13, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
